HR+, HER2-, Advanced Breast Cancer (DBCOND0140304)

Identifiers

Synonyms

HR+HER2- Advanced Breast Cancer / HR+/HER2- Advanced Breast Cancer / Advanced HR + HER2 - breast cancer

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Abemaciclib	A medication used to treat HR+ HER2- advanced or metastatic breast cancer.	Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter Cyclin-dependent kinase 4target Cyclin-dependent kinase 6target Albumincarrier alpha1-acid glycoproteincarrier Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 2transporter Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2D6enzyme
Alpelisib	Alpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer. This cancer must be hormone receptor (HR)-positive, human epidermal growth factor...	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget Cytochrome P450 3A4enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C19enzyme Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter
Letrozole	An aromatase inhibitor used to treat breast cancer in postmenopausal women.	Aromatasetarget Cytochrome P450 3A4enzyme Cytochrome P450 2A6enzyme Aromataseenzyme Cytochrome P450 2C19enzyme UDP-glucuronosyltransferase 2B7enzyme Albumincarrier ATP-dependent translocase ABCB1transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06625333	A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT06148506	A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia	No drug interventions	Not Available	Not Available	recruiting
NCT05983107	Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer	Everolimus Tucidinostat	treatment	2	recruiting
NCT05586841	Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study	Dalpiciclib Tucidinostat	treatment	1	not_yet_recruiting
NCT06556862	Exploration of Dalpiciclib + Tucidinostat in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor	Dalpiciclib Tucidinostat	treatment	2	not_yet_recruiting
NCT04473040	Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer	Alpelisib	Not Available	Not Available	available